Stoke Therapeutics, Inc. Nonoperating Income (Expense) in USD from 2018 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Stoke Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2018 to Q3 2025.
  • Stoke Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2025 was $3.47M, a 3% decline year-over-year.
  • Stoke Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2025 was $13.4M, a 12.9% increase year-over-year.
  • Stoke Therapeutics, Inc. annual Nonoperating Income (Expense) for 2024 was $12.4M, a 23% increase from 2023.
  • Stoke Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $10.1M, a 206% increase from 2022.
  • Stoke Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $3.29M, a 1165% increase from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)

Stoke Therapeutics, Inc. Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $13.4M $3.47M -$107K -3% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-04
Q2 2025 $13.5M $3.82M +$170K +4.66% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-12
Q1 2025 $13.3M $2.92M +$919K +46% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-13
Q4 2024 $12.4M $3.17M +$544K +20.7% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-18
Q3 2024 $11.8M $3.57M +$881K +32.7% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-04
Q2 2024 $11M $3.65M +$1.04M +39.8% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-12
Q1 2024 $9.93M $2M -$147K -6.85% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-13
Q4 2023 $10.1M $2.63M +$1.11M +73% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-18
Q3 2023 $8.97M $2.69M +$1.66M +160% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 $7.31M $2.61M +$2.02M +345% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $5.29M $2.15M +$2M +1369% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 $3.29M $1.52M +$1.44M +1849% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-25
Q3 2022 $1.85M $1.04M +$951K +1106% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $896K $586K +$524K +845% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $372K $146K +$112K +329% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $260K $78K +$53K +212% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-06
Q3 2021 $207K $86K +$59K +219% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $148K $62K +$9K +17% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $139K $34K -$662K -95.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $801K $25K -$884K -97.3% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 $1.69M $27K -$1.21M -97.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $2.9M $53K -$573K -91.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 $3.47M $696K +$116K +20% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $3.35M $909K Oct 1, 2019 Dec 31, 2019 10-K 2021-03-09
Q3 2019 $1.24M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $626K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $580K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15

Stoke Therapeutics, Inc. Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $12.4M +$2.32M +23% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-18
2023 $10.1M +$6.79M +206% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-18
2022 $3.29M +$3.03M +1165% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-25
2021 $260K -$541K -67.5% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-06
2020 $801K -$2.55M -76.1% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-10
2019 $3.35M +$3.09M +1190% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-09
2018 $260K Jan 1, 2018 Dec 31, 2018 10-K 2020-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.